Upstream Bio (NASDAQ:UPB - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Friday.
Upstream Bio Price Performance
Shares of UPB stock traded up $0.44 during trading hours on Friday, hitting $11.27. 207,137 shares of the company's stock traded hands, compared to its average volume of 333,006. The stock's fifty day simple moving average is $8.60 and its two-hundred day simple moving average is $11.39. Upstream Bio has a 12-month low of $5.14 and a 12-month high of $29.46.
Upstream Bio (NASDAQ:UPB - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The company had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.71 million. Equities research analysts forecast that Upstream Bio will post -4.3 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the company. Northern Trust Corp bought a new position in shares of Upstream Bio during the 4th quarter valued at about $2,363,000. Legal & General Group Plc bought a new position in shares of Upstream Bio during the 4th quarter valued at about $28,000. Barclays PLC bought a new position in shares of Upstream Bio during the 4th quarter valued at about $445,000. MetLife Investment Management LLC bought a new position in shares of Upstream Bio during the 4th quarter valued at about $181,000. Finally, Corebridge Financial Inc. bought a new position in shares of Upstream Bio during the 4th quarter valued at about $142,000.
Upstream Bio Company Profile
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
